204 related articles for article (PubMed ID: 34453851)
21. Relapse in stage I(E) diffuse large B-cell lymphoma.
Nijland M; Boslooper K; van Imhoff G; Kibbelaar R; Joosten P; Storm H; van Roon EN; Diepstra A; Kluin-Nelemans HC; Hoogendoorn M
Hematol Oncol; 2018 Apr; 36(2):416-421. PubMed ID: 29083044
[TBL] [Abstract][Full Text] [Related]
22. Prediction of Prognosis for Patients with Diffuse Large B-Cell Lymphoma Refractory to or in First Relapse After Initial R-CHOP Therapy: A Single-Institution Study.
Yamamoto M; Watanabe K; Fukuda T; Miura O
Anticancer Res; 2017 May; 37(5):2655-2662. PubMed ID: 28476841
[TBL] [Abstract][Full Text] [Related]
23. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
24. Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.
Vitolo U; Trněný M; Belada D; Burke JM; Carella AM; Chua N; Abrisqueta P; Demeter J; Flinn I; Hong X; Kim WS; Pinto A; Shi YK; Tatsumi Y; Oestergaard MZ; Wenger M; Fingerle-Rowson G; Catalani O; Nielsen T; Martelli M; Sehn LH
J Clin Oncol; 2017 Nov; 35(31):3529-3537. PubMed ID: 28796588
[TBL] [Abstract][Full Text] [Related]
25. A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA.
Sehn LH; Martelli M; Trněný M; Liu W; Bolen CR; Knapp A; Sahin D; Sellam G; Vitolo U
J Hematol Oncol; 2020 Jun; 13(1):71. PubMed ID: 32505213
[TBL] [Abstract][Full Text] [Related]
26. Refractory or relapsed aggressive B-cell lymphoma failing (R)-CHOP: an analysis of patients treated on the RICOVER-60 trial.
Glass B; Dohm AJ; Truemper LH; Pfreundschuh M; Bleckmann A; Wulf GG; Rosenwald A; Ziepert M; Schmitz N;
Ann Oncol; 2017 Dec; 28(12):3058-3064. PubMed ID: 29232438
[TBL] [Abstract][Full Text] [Related]
27. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.
Delarue R; Tilly H; Mounier N; Petrella T; Salles G; Thieblemont C; Bologna S; Ghesquières H; Hacini M; Fruchart C; Ysebaert L; Fermé C; Casasnovas O; Van Hoof A; Thyss A; Delmer A; Fitoussi O; Molina TJ; Haioun C; Bosly A
Lancet Oncol; 2013 May; 14(6):525-33. PubMed ID: 23578722
[TBL] [Abstract][Full Text] [Related]
28. Prognostic model for relapsed/refractory transplant-ineligible diffuse large B-cell lymphoma utilizing the lymphocyte-to-monocyte ratio.
Ide D; Fujino T; Kobayashi T; Egashira A; Miyashita A; Mizuhara K; Isa R; Tsukamoto T; Mizutani S; Uchiyama H; Kaneko H; Uoshima N; Kawata E; Taniwaki M; Shimura Y; Kuroda J
Int J Hematol; 2024 Jun; 119(6):697-706. PubMed ID: 38492199
[TBL] [Abstract][Full Text] [Related]
29. Additional survival benefit of involved-lesion radiation therapy after R-CHOP chemotherapy in limited stage diffuse large B-cell lymphoma.
Kwon J; Kim IH; Kim BH; Kim TM; Heo DS
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):91-8. PubMed ID: 25721091
[TBL] [Abstract][Full Text] [Related]
30. High Incidence and Clinical Significance of MYC Rearrangements in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
Schrader AMR; Jansen PM; Vermeer MH; Kleiverda JK; Vermaat JSP; Willemze R
Am J Surg Pathol; 2018 Nov; 42(11):1488-1494. PubMed ID: 30113335
[TBL] [Abstract][Full Text] [Related]
31. Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.
van Imhoff GW; McMillan A; Matasar MJ; Radford J; Ardeshna KM; Kuliczkowski K; Kim W; Hong X; Goerloev JS; Davies A; Barrigón MDC; Ogura M; Leppä S; Fennessy M; Liao Q; van der Holt B; Lisby S; Hagenbeek A
J Clin Oncol; 2017 Feb; 35(5):544-551. PubMed ID: 28029326
[TBL] [Abstract][Full Text] [Related]
32. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography.
Pinnix CC; Dabaja B; Ahmed MA; Chuang HH; Costelloe C; Wogan CF; Reed V; Romaguera JE; Neelapu S; Oki Y; Rodriguez MA; Fayad L; Hagemeister FB; Nastoupil L; Turturro F; Fowler N; Fanale MA; Nieto Y; Khouri IF; Ahmed S; Medeiros LJ; Davis RE; Westin J
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):113-21. PubMed ID: 25863759
[TBL] [Abstract][Full Text] [Related]
33. Improved outcome for very elderly patients with diffuse large B-cell lymphoma in the immunochemotherapy era.
Hasselblom S; Stenson M; Werlenius O; Sender M; Lewerin C; Hansson U; Nilsson-Ehle H; Andersson PO
Leuk Lymphoma; 2012 Mar; 53(3):394-9. PubMed ID: 21864039
[TBL] [Abstract][Full Text] [Related]
34. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Récher C; Coiffier B; Haioun C; Molina TJ; Fermé C; Casasnovas O; Thiéblemont C; Bosly A; Laurent G; Morschhauser F; Ghesquières H; Jardin F; Bologna S; Fruchart C; Corront B; Gabarre J; Bonnet C; Janvier M; Canioni D; Jais JP; Salles G; Tilly H;
Lancet; 2011 Nov; 378(9806):1858-67. PubMed ID: 22118442
[TBL] [Abstract][Full Text] [Related]
35. Rituximab as consolidation therapy did not improve outcome in patients with diffuse large B-cell lymphoma at complete response after dose-dense chemotherapy (CHOP-14).
Avilès A; Nambo MJ; Huerta-Guzmàn J; Silva L; Neri N
Cancer Biother Radiopharm; 2015 Apr; 30(3):107-10. PubMed ID: 25871407
[TBL] [Abstract][Full Text] [Related]
36. The prognostic value of PET/CT evaluation with Deauville score on the recurrence and survival in diffuse large B-cell lymphoma: a multi-institutional study of KROG 17-02.
Lee JW; Oh D; Eom KY; Kim JH; Kim WC; Chung MJ; Lee JH
Clin Exp Metastasis; 2020 Feb; 37(1):125-131. PubMed ID: 31555945
[TBL] [Abstract][Full Text] [Related]
37. Clinical features and treatment outcomes of primary cutaneous B-cell lymphoma: a single-center analysis in South Korea.
Kim MJ; Hong ME; Maeng CH; Jung HA; Hong JY; Choi MK; Kim SJ; Ko YH; Kim WS
Int J Hematol; 2015 Mar; 101(3):273-8. PubMed ID: 25552248
[TBL] [Abstract][Full Text] [Related]
38. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
[TBL] [Abstract][Full Text] [Related]
39. Indurated Plaques on the Legs: Think Lymphoma.
Watts-Santos A; Cuellar-Barboza A; Ramos-Cavazos CJ; Villarreal-Martinez A; Ocampo-Candiani J; Herz-Ruelas ME
Acta Dermatovenerol Croat; 2021 Jul; 29(2):114-115. PubMed ID: 34477080
[TBL] [Abstract][Full Text] [Related]
40. Treatment and outcomes in patients with primary cutaneous B-cell lymphoma: the BC Cancer Agency experience.
Hamilton SN; Wai ES; Tan K; Alexander C; Gascoyne RD; Connors JM
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):719-25. PubMed ID: 24001373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
